200 related articles for article (PubMed ID: 16648296)
1. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone.
Yakar S; Bouxsein ML; Canalis E; Sun H; Glatt V; Gundberg C; Cohen P; Hwang D; Boisclair Y; Leroith D; Rosen CJ
J Endocrinol; 2006 May; 189(2):289-99. PubMed ID: 16648296
[TBL] [Abstract][Full Text] [Related]
2. Skeletal response of male mice to anabolic hormone therapy in the absence of the Igfals gene.
Kennedy OD; Sun H; Wu Y; Courtland HW; Williams GA; Cardoso L; Basta-Pljakic J; Schaffler MB; Yakar S
Endocrinology; 2014 Mar; 155(3):987-99. PubMed ID: 24424061
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone.
Bikle DD; Sakata T; Leary C; Elalieh H; Ginzinger D; Rosen CJ; Beamer W; Majumdar S; Halloran BP
J Bone Miner Res; 2002 Sep; 17(9):1570-8. PubMed ID: 12211426
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I.
Wang Y; Sakata T; Elalieh HZ; Munson SJ; Burghardt A; Majumdar S; Halloran BP; Bikle DD
J Endocrinol; 2006 May; 189(2):279-87. PubMed ID: 16648295
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of IGF-1 directly regulate bone growth and density.
Yakar S; Rosen CJ; Beamer WG; Ackert-Bicknell CL; Wu Y; Liu JL; Ooi GT; Setser J; Frystyk J; Boisclair YR; LeRoith D
J Clin Invest; 2002 Sep; 110(6):771-81. PubMed ID: 12235108
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy-associated plasma protein-A modulates the anabolic effects of parathyroid hormone in mouse bone.
Clifton KB; Conover CA
Bone; 2015 Dec; 81():413-416. PubMed ID: 26297833
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance.
Haluzik M; Yakar S; Gavrilova O; Setser J; Boisclair Y; LeRoith D
Diabetes; 2003 Oct; 52(10):2483-9. PubMed ID: 14514630
[TBL] [Abstract][Full Text] [Related]
8. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program.
Rosen CJ; Ackert-Bicknell CL; Adamo ML; Shultz KL; Rubin J; Donahue LR; Horton LG; Delahunty KM; Beamer WG; Sipos J; Clemmons D; Nelson T; Bouxsein ML; Horowitz M
Bone; 2004 Nov; 35(5):1046-58. PubMed ID: 15542029
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 production.
Courtland HW; Sun H; Beth-On M; Wu Y; Elis S; Rosen CJ; Yakar S
J Bone Miner Res; 2011 Apr; 26(4):761-8. PubMed ID: 20928887
[TBL] [Abstract][Full Text] [Related]
10. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
[TBL] [Abstract][Full Text] [Related]
12. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism.
Yakar S; Rosen CJ; Bouxsein ML; Sun H; Mejia W; Kawashima Y; Wu Y; Emerton K; Williams V; Jepsen K; Schaffler MB; Majeska RJ; Gavrilova O; Gutierrez M; Hwang D; Pennisi P; Frystyk J; Boisclair Y; Pintar J; Jasper H; Domene H; Cohen P; Clemmons D; LeRoith D
FASEB J; 2009 Mar; 23(3):709-19. PubMed ID: 18952711
[TBL] [Abstract][Full Text] [Related]
13. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
14. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo.
Bouxsein ML; Rosen CJ; Turner CH; Ackert CL; Shultz KL; Donahue LR; Churchill G; Adamo ML; Powell DR; Turner RT; Muller R; Beamer WG
J Bone Miner Res; 2002 Apr; 17(4):570-9. PubMed ID: 11918215
[TBL] [Abstract][Full Text] [Related]
15. The insulin-like growth factor-1 binding protein acid-labile subunit alters mesenchymal stromal cell fate.
Fritton JC; Kawashima Y; Mejia W; Courtland HW; Elis S; Sun H; Wu Y; Rosen CJ; Clemmons D; Yakar S
J Biol Chem; 2010 Feb; 285(7):4709-14. PubMed ID: 20007694
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone.
Pfeilschifter J; Laukhuf F; Müller-Beckmann B; Blum WF; Pfister T; Ziegler R
J Clin Invest; 1995 Aug; 96(2):767-74. PubMed ID: 7635970
[TBL] [Abstract][Full Text] [Related]
17. CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.
Liu F; Lee SK; Adams DJ; Gronowicz GA; Kream BE
Bone; 2007 Apr; 40(4):1135-43. PubMed ID: 17275432
[TBL] [Abstract][Full Text] [Related]
18. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice.
Yamaguchi M; Ogata N; Shinoda Y; Akune T; Kamekura S; Terauchi Y; Kadowaki T; Hoshi K; Chung UI; Nakamura K; Kawaguchi H
Endocrinology; 2005 Jun; 146(6):2620-8. PubMed ID: 15718274
[TBL] [Abstract][Full Text] [Related]
19. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow.
Nishida S; Yamaguchi A; Tanizawa T; Endo N; Mashiba T; Uchiyama Y; Suda T; Yoshiki S; Takahashi HE
Bone; 1994; 15(6):717-23. PubMed ID: 7873302
[TBL] [Abstract][Full Text] [Related]
20. Congenic mice provide in vivo evidence for a genetic locus that modulates serum insulin-like growth factor-I and bone acquisition.
Delahunty KM; Shultz KL; Gronowicz GA; Koczon-Jaremko B; Adamo ML; Horton LG; Lorenzo J; Donahue LR; Ackert-Bicknell C; Kream BE; Beamer WG; Rosen CJ
Endocrinology; 2006 Aug; 147(8):3915-23. PubMed ID: 16675518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
